Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Amount of analgesia · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Patient-controlled analgesia (PCA) pethidine showed no clear difference in daily mean opiate intake per hour compared with staff-controlled delivery of pethidine; GRADE not reported.
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Patient-controlled analgesia (PCA) pethidine showed no clear difference in average pain scores (0-100 VAS) compared with staff-controlled delivery of pethidine; GRADE not reported.
1 finding from 1 review
Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) led to lower daily mean opiate intake per hour compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) showed no clear difference in average pain scores (0-100 VAS) compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review
Duration of pain control therapy (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) led to lower duration of pain control therapy (days) compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review
Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via pharmacokinetically based PCA (PKPCA) led to higher daily mean opiate intake per hour compared with morphine via patient-controlled analgesia (PCA); GRADE not reported.
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via pharmacokinetically based PCA (PKPCA) led to lower average pain scores (0-100 VAS) compared with morphine via patient-controlled analgesia (PCA); GRADE not reported.
1 finding from 1 review
Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review